BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Charles K. Gayer
CEOCharles K. Gayer
Employees
435
Employees435
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
435
Employees435

BCRX Key Statistics

Market cap
2.22B
Market cap2.22B
Price-Earnings ratio
-4.94
Price-Earnings ratio-4.94
Dividend yield
Dividend yield
Average volume
6.43M
Average volume6.43M
High today
$9.00
High today$9.00
Low today
$8.69
Low today$8.69
Open price
$8.78
Open price$8.78
Volume
2.48M
Volume2.48M
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

With a market cap of 2.22B, BioCryst(BCRX) trades at $8.69. The stock has a price-to-earnings ratio of -4.94.

On 2026-05-20, BioCryst(BCRX) stock moved within a range of $8.69 to $9.00. With shares now at $8.69, the stock is trading 0.0% above its intraday low and -3.4% below the session's peak.

Trading activity shows a volume of 2.48M, compared to an average daily volume of 6.43M.

The stock's 52-week range extends from a low of $6.00 to a high of $11.31.

The stock's 52-week range extends from a low of $6.00 to a high of $11.31.

BCRX News

TipRanks 19h
BioCryst Insider Makes a Six-Figure Move That Investors Can’t Ignore

New insider activity at BioCryst ( (BCRX) ) has taken place on May 19, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharper dec...

TipRanks 21h
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks

BioCryst Pharmaceuticals ((BCRX)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level dat...

Simply Wall St 4d
European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst

In early May 2026, BioCryst Pharmaceuticals reported first-quarter revenue of US$156.41 million but a net loss of US$721.81 million, while maintaining full-year...

European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

More BCRX News

Simply Wall St 6d
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case

BioCryst Pharmaceuticals (NasdaqGS:BCRX) has granted Neopharmed Gentili exclusive European licensing rights to navenibart for hereditary angioedema. The agreem...

BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.